Examkin

Question

Difficulty: HardMonitoring and Treatment Evaluation

A patient is currently receiving treatment in the cardiovascular step-down unit for a massive pulmonary embolism diagnosed three days ago. She was initially started on an unfractionated heparin infusion. Today, her daily laboratory monitoring reveals a precipitous drop in her platelet count. She has also developed a new, painful, swollen right calf.

Hospital DayPlatelet Count
Day 1 (Admission)240,000/μL240,000/\mu L
Day 2215,000/μL215,000/\mu L
Day 3160,000/μL160,000/\mu L
Day 4 (Today)95,000/μL95,000/\mu L

A serotonin release assay is sent, and a clinical diagnosis of heparin-induced thrombocytopenia (HIT) with a new deep vein thrombosis is suspected.

Arrange the following management and monitoring steps in the correct chronological sequence to appropriately treat this patient's condition and safely transition her to long-term oral anticoagulation with warfarin.

  1. 1Discontinue the unfractionated heparin infusion immediately.
  2. 2Initiate a continuous infusion of a non-heparin direct thrombin inhibitor (e.g., argatroban).
  3. 3Monitor serial complete blood counts until the platelet count recovers to ≥150,000/μL\geq 150,000/\mu L.
  4. 4Initiate overlapping oral warfarin therapy at a standard starting dose.
  5. 5Discontinue the direct thrombin inhibitor once the INR is between 2.02.0 and 3.03.0 for at least 24 hours.

Answer

The correct chronological sequence is to first discontinue heparin, then initiate a direct thrombin inhibitor, monitor platelets until they recover, initiate overlapping warfarin, and finally discontinue the direct thrombin inhibitor once the INR is therapeutic.
The standard of care for heparin-induced thrombocytopenia (HIT) involves immediately discontinuing all heparin products and initiating a non-heparin anticoagulant like argatroban. Transitioning to long-term oral warfarin requires strict monitoring: warfarin cannot be started until the platelet count recovers to at least 150,000/μL150,000/\mu L. Once started, warfarin must be overlapped with the parenteral anticoagulant for at least 5 days and until the INR is strictly therapeutic (2.02.0-3.03.0) for 24-48 hours before the parenteral agent can be safely discontinued.

Step-by-Step Solution

1
Discontinue unfractionated heparin
Halts further immune complex formation
Heparin is the offending agent causing antibody-mediated platelet activation.
2
Start argatroban
Provides immediate alternative anticoagulation
Patients with heparin-induced thrombocytopenia have a high risk of new or progressive thrombosis and require ongoing systemic anticoagulation.
3
Monitor platelet counts
Confirms recovery from the acute consumptive phase
Platelet recovery (typically ≥150,000/μL\geq 150,000/\mu L) indicates that the acute prothrombotic state is resolving.
4
Initiate warfarin
Begins transition to long-term oral therapy
Warfarin can now be safely introduced without the high risk of venous limb gangrene caused by early protein C depletion.
5
Monitor INR and discontinue argatroban
Completes the transition to monotherapy
Overlap ensures continuous anticoagulation until warfarin fully inhibits vitamin K-dependent clotting factors.

Key Concept

In patients with heparin-induced thrombocytopenia, warfarin should only be initiated after platelets recover to ≥150,000/μL\geq 150,000/\mu L, followed by an overlap period with a non-heparin parenteral anticoagulant until the INR is therapeutic.
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic